{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T22:08:53Z","timestamp":1785449333777,"version":"3.56.0"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T00:00:00Z","timestamp":1780790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T00:00:00Z","timestamp":1780790400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"DOI":"10.1186\/s13045-026-01810-w","type":"journal-article","created":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T10:23:20Z","timestamp":1780827800000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Novel BTK inhibitors and degraders for relapsed\/refractory CLL\/SLL: latest updates from ASH 2025 annual meeting"],"prefix":"10.1186","volume":"19","author":[{"given":"Pritika","family":"Sharma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heng","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,7]]},"reference":[{"issue":"11","key":"1810_CR1","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1182\/blood.2024024476","volume":"146","author":"JP Sharman","year":"2025","unstructured":"Sharman JP, Egyed M, Jurczak W, Skarbnik A, Patel K, Flinn IW, Kamdar M, Munir T, Walewska R, Hughes M, Fogliatto LM, Herishanu Y, Banerji V, Follows G, Walker P, Ghia P, Janssens A, Byrd JC, Ferrant E, Ferrajoli A, Wierda WG, Wachira CW, Suterwala BT, Miranda P, Munugalavadla V, Wun C-C, Woyach JA. Acalabrutinib-obinutuzumab improves survival vs chemoimmunotherapy in treatment-naive CLL in the 6-year follow-up of ELEVATE-TN. Blood. 2025;146(11):1276\u201385.","journal-title":"Blood"},{"issue":"7","key":"1810_CR2","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1200\/JCO-24-02265","volume":"43","author":"M Shadman","year":"2025","unstructured":"Shadman M, Munir T, Robak T, Brown JR, Kahl BS, Ghia P, Giannopoulos K, \u0160imkovi\u010d M, \u00d6sterborg A, Laurenti L, Walker PA, Opat SS, Ciepluch H, Greil R, Hanna M, Tani M, Trn\u011bn\u00fd M, Brander D, Flinn IW, Grosicki S, Verner E, Tedeschi A, de Guibert S, Tumyan G, Laribi K, Garc\u00eda-Marco JA, Li JY, Tian T, Liu Y, Korolkiewicz R, et al. Zanubrutinib Versus Bendamustine and Rituximab in Patients With Treatment-Na\u00efve Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma: Median 5-Year Follow-Up of SEQUOIA. J Clin Oncol. 2025;43(7):780\u20137.","journal-title":"J Clin Oncol"},{"issue":"6","key":"1810_CR3","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1200\/JCO-25-02380","volume":"44","author":"W Jurczak","year":"2026","unstructured":"Jurczak W, Kwiatek M, Czyz J, Roberto de Mattos E, Eom KS, Egle A, Panovska A, Popova ZG, Shih HJ, Casado Montero LF, Sportoletti P, Hua VM, D\u2019Olimpio JT, Iida S, Ito R, Bao K, Fink A, Su W, Ruppert AS, Levy A, Wrobel T. BRUIN CLL-313: Randomized Phase III Trial of Pirtobrutinib Versus Bendamustine Plus Rituximab in Untreated Patients With Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma. J Clin Oncol. 2026;44(6):466\u201375.","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"1810_CR4","doi-asserted-by":"publisher","first-page":"3892","DOI":"10.1182\/blood-2025-3892","volume":"146","author":"N Jain","year":"2025","unstructured":"Jain N, Coombs C, D\u2019Olimpio J, Shah N, Barrientos J, Lee ST, Brander D, Nemunaitis J, Gillis-Smith A, Ma S, Kirita S, Yoshida K, Sawa M, Miyamoto K, Arimura A, Wierda W, Gandhi V, Pinilla-Ibarz J. Docirbrutinib (AS-1763), a novel non-COVALENT pan-mutant BTK inhibitor, demonstrates durable clinical responses in patients with previously treated B-cell malignancies: Data from an ongoing Phase 1b study. Blood. 2025;146(Supplement 1):3892\u20133892.","journal-title":"Blood"},{"issue":"Supplement 1","key":"1810_CR5","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1182\/blood-2025-87","volume":"146","author":"J Woyach","year":"2025","unstructured":"Woyach J, Brander D, Hu B, Rogers K, Omer Z, Curran E, Stephens D, Sitlinger A, Chen Y, Anthony S, Chen Y, Shang K, Byrd J. Updates of R\/R CLL with prior exposure to Bruton\u2019s tyrosine kinase (BTK) inhibitor and\/or bcl-2 inhibitor in the Phase 1 trial of LP-168 (Rocbrutinib), a novel COVALENT and non-COVALENT BTK inhibitor. Blood. 2025;146(Supplement 1):87\u201387.","journal-title":"Blood"},{"issue":"Supplement 1","key":"1810_CR6","doi-asserted-by":"publisher","first-page":"3896","DOI":"10.1182\/blood-2025-3896","volume":"146","author":"Y Song","year":"2025","unstructured":"Song Y, Cai Q, Zhou K, Jin Z, Jiang M, Sun X, Zhang L, Yang H, Li L, Ding K, Qi J, Zhou M, Jing H, Yang W, Zhou H, Ma J, Peng Z, Xu W, Yu L, Shi Y, Cui G, Wang Z, Liu N, Lou Y, Shen Y, Chen Y, Tan F, Zhu J. Efficacy and safety of rocbrutinib, a highly selective 4th-generation BTK inhibitor, in Chinese patients with chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL). Blood. 2025;146(Supplement 1):3896\u20133896.","journal-title":"Blood"},{"issue":"Supplement 1","key":"1810_CR7","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1182\/blood-2025-1532","volume":"146","author":"B Gordon","year":"2025","unstructured":"Gordon B, Cool L, Muhowski E, Yu L, Ravikrishnan J, Benrashid S, Mitchell A, He A, Misra S, Lai T-H, Thangavadivel S, Marr A, Urrutia J, Leimbach C, Karnati N, Zhao SL, Sonam S, Kumari S, Perry E, Rogers K, Kittai A, Bhat S, Alsouqi A, Muthusamy N, Byrd J, Sampath D, Lapalombella R, Peterson B, Chen Y, Anthony S, et al. Targeting BTKi-resistant CLL using the dual irreversible\/reversible 4th generation BTK inhibitor rocbrutinib. Blood. 2025;146(Supplement 1):1532\u20131532.","journal-title":"Blood"},{"issue":"Supplement 1","key":"1810_CR8","doi-asserted-by":"publisher","first-page":"3889","DOI":"10.1182\/blood-2025-3889","volume":"146","author":"K Zhou","year":"2025","unstructured":"Zhou K, Wang T, Yang W, Mi J-Q, Gao S, Zhu H, Guo X, Ding K, Xiang Y, Cai H, Cui G, Zhuang Y, Jing H, Su L, Huang R, Qiu L, Geyer M, Hui W, Chong G, Zheng M, Wang Y, Li Y, Fang K, Cheah C, Li J. Phase 1\/2 studies of DZD8586 in CLL\/SLL patients after COVALENT and non-COVALENT BTK inhibitors and BTK degraders \u2013 extended follow-up report. Blood. 2025;146(Supplement 1):3889\u20133889.","journal-title":"Blood"},{"issue":"Supplement 1","key":"1810_CR9","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1182\/blood-2025-86","volume":"146","author":"Z Omer","year":"2025","unstructured":"Omer Z, Danilov A, Forconi F, Munir T, Gleeson M, Shah N, Collins G, Alencar A, Robertson J, Cohen J, Dixit K, Brander D, Byrd J, Winter A, Smith J, El-Sharkawi D, Kwiatek M, Hus I, Islam P, Grosicki S, Tees M, Zenz T, Romejko-Jarosinska J, Injac S, Jurczak W. Bexobrutideg (NX-5948), a novel Bruton\u2019s tyrosine kinase (BTK) degrader, demonstrates rapid and durable clinical responses in Relapsed\/Refractory chronic lymphocytic leukemia (CLL): New and updated findings from an ongoing Phase 1a\/b trial. Blood. 2025;146(Supplement 1):86\u201386.","journal-title":"Blood"},{"key":"1810_CR10","doi-asserted-by":"crossref","unstructured":"Zhong G, Kong R, Feng S, Wang C, Hao Q, Xie W, Zhou X. Targeted protein degradation in hematologic malignancies: latest updates from the 2023 ASH annual meeting. Journal of Hematology & Oncology 2024, 17(1):14.","DOI":"10.1186\/s13045-024-01533-w"},{"issue":"Supplement 1","key":"1810_CR11","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1182\/blood-2025-85","volume":"146","author":"I Ahn","year":"2025","unstructured":"Ahn I, Parrondo R, Thompson M, Frustaci A, Allan J, Ghia P, Mocanu I, Roos Weil D, Tam C, Stilgenbauer S, Trotman J, Scarfo L, Lamanna N, Zhang Y, Xu L, By K, Fabre S, Persky D, Agarwal A, Seymour J. Updated efficacy and safety results of the Bruton tyrosine kinase (BTK) degrader BGB-16673 in patients with relapsed\/refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL) from the ongoing phase 1 CaDAnCe-101 study. Blood. 2025;146(Supplement 1):85\u201385.","journal-title":"Blood"}],"container-title":["Journal of Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-026-01810-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-026-01810-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-026-01810-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T10:23:22Z","timestamp":1780827802000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13045-026-01810-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,7]]},"references-count":11,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1810"],"URL":"https:\/\/doi.org\/10.1186\/s13045-026-01810-w","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,7]]},"assertion":[{"value":"5 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This is not applicable for this summary.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"This is not applicable for this summary.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"40"}}